Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas

Publisher Website
Google Scholar
Abstract
In late September 2004, the cardiovascular risks identified in a placebo-controlled adenoma-prevention trial that was terminated early precipitated the voluntary withdrawal from the market of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib.1 Later that year, in another adenoma-prevention trial, the COX-2 inhibitor, celecoxib, was also associated with an increase in the risk of cardiovascular events.2 For this reason, on December 17, 2004, the data and safety monitoring boards of two celecoxib trials recommended stopping drug administration in the trials.2,3 Articles describing the cardiovascular risks seen in the two adenoma prevention trials were published rapidly.1,4 However, in the absence of evidence . . .